Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to 90572.03%.

  • Crinetics Pharmaceuticals' EBITDA Margin changed N/A to 90572.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 27553.16%, marking a year-over-year decrease of 10847300.0%. This contributed to the annual value of 28722.04% for FY2024, which is 234984900.0% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' EBITDA Margin is 90572.03%.
  • Crinetics Pharmaceuticals' EBITDA Margin's 5-year high stood at 1163.75% during Q1 2022, with a 5-year trough of 90572.03% in Q3 2025.
  • For the 5-year period, Crinetics Pharmaceuticals' EBITDA Margin averaged around 16181.98%, with its median value being 9977.68% (2022).
  • The largest annual percentage gain for Crinetics Pharmaceuticals' EBITDA Margin in the last 5 years was 73924100bps (2025), contrasted with its biggest fall of -159323600bps (2025).
  • Over the past 5 years, Crinetics Pharmaceuticals' EBITDA Margin (Quarter) stood at 2890.91% in 2021, then tumbled by -114bps to 6193.51% in 2022, then crashed by -164bps to 16363.58% in 2023, then fell by -14bps to 18645.36% in 2024, then crashed by -386bps to 90572.03% in 2025.
  • Its last three reported values are 90572.03% in Q3 2025, 11252.96% for Q2 2025, and 26519.39% during Q1 2025.